SALBUTAMOL DELIVERING TRANSDERMAL DOSAGE FORM BASED ON OSMOREGULATORY PRINCIPLE

被引:7
作者
JAIN, SK
VYAS, SP
DIXIT, V
机构
[1] Department of Pharmaceutical Sciences, Dr. H.S. Gour Vishwavidyalaya, Sagar, MP
关键词
D O I
10.3109/03639049009074384
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A transdermal drug delivery system of Salbutamol was developed which released the drug following zero order kinetics. The designed system essentially based on trilaminated matrix concept. The delivery of drug from the system affected by osmotic phenomenon where sodium chloride was used as an osmogent. To establish the desired release rate polyethylene glycol 4000 (PEG 4000) was used as channelising agent in rate controlling membrance of cellulose acetate. The designed systems exhibiting zero-order release rate, were studied for the in-vitro skin permeation. The product which was having skin permeability rate 115 mcg/hr/cm2 was selected for the in-vivo evaluation. The forced expiratory volume (FEV1) and drug plasma concentration were monitored periodically. The study revealed that designed osmoregulatory transdermal drug delivery system of Salbutamol could be used successfully with improved therapeutic response and holds promise for the clinical studies. © 1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
引用
收藏
页码:1565 / 1577
页数:13
相关论文
共 10 条
[1]   SPACING BETWEEN DOSES ON A THRICE-DAILY REGIMEN [J].
ALFREDSSON, LA ;
NORELL, SE .
BRITISH MEDICAL JOURNAL, 1981, 282 (6269) :1036-1036
[2]   ORAL CONTROLLED RELEASE DOSAGE FORMS - A REVIEW [J].
DEHAAN, P ;
LERK, CF .
PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1984, 6 (02) :57-67
[3]  
GOLDSTEIN DA, 1987, EUR J CLIN PHARMACOL, V36, P631
[4]   DETERMINATION OF SALBUTAMOL IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION [J].
HUTCHINGS, MJ ;
PAULL, JD ;
MORGAN, DJ .
JOURNAL OF CHROMATOGRAPHY, 1983, 277 (OCT) :423-426
[5]  
IYER BV, 1979, J PHARMN SCI, V68, P783
[6]  
SHAW JE, 1978, DRUG METAB REV, V8, P223
[7]  
SHIGBAL DM, 1984, INDIAN DRUGS, V21, P398
[8]  
WALKER SR, 1972, CLIN PHARMACOL THER, V13, P861
[9]  
1980, BRIT PHARM, V2, pA53
[10]  
[No title captured], Patent No. 4336243